has an active malignancy or history of solid or hematological malignancies within 5 years prior to enrollment in the study. patients who had basal or squamous cell carcinoma-in-situ of the skin that was diagnosed > 2 years prior to the study enrollment and not currently being treated are eligible for study enrollment. patient is pregnant or breast-feeding. patient, in the opinion of the investigator, is unlikely to survive for ≥48 hours from the time of screening. patient has any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study. patient with alanine aminotransferase (alt) or aspartate transaminase (ast) > 3x upper limit of normal (uln) and/or total bilirubin > 2xuln at baseline patient requires treatment with the cytochrome p450 1a2 (cyp1a2) inhibitors, ciprofloxacin (cipro®) and/or fluvoxamine (luvox®) patients participating in any other clinical trial with an investigational drug product or procedure recipients of solid organ and/or hematopoietic cell transplantation patient is known to have end stage renal disease (esrd) and was being treated with maintenance hemodialysis or peritoneal dialysis prior to the current hospitalization. note: patients who initiated rrt due to acute kidney injury during their current hospitalization will be eligible for the study

has an active malignancy or history of solid or hematological malignancies within 5 years prior to enrollment in the study. patients who had basal or squamous cell carcinoma-in-situ of the skin that was diagnosed > 2 years prior to the study enrollment and not currently being treated are eligible for study enrollment. patient is pregnant or breast-feeding. patient, in the opinion of the investigator, is unlikely to survive for ≥48 hours from the time of screening. patient has any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study. patient with alanine aminotransferase (alt) or aspartate transaminase (ast) > 3x upper limit of normal (uln) and/or total bilirubin > 2xuln at baseline patient requires treatment with the cytochrome p450 1a2 (cyp1a2) inhibitors, ciprofloxacin (cipro®) and/or fluvoxamine (luvox®) patients participating in any other clinical trial with an investigational drug product or procedure recipients of solid organ and/or hematopoietic cell transplantation patient is known to have end stage renal disease (esrd) and was being treated with maintenance hemodialysis or peritoneal dialysis prior to the current hospitalization. note: patients who initiated rrt due to acute kidney injury during their current hospitalization will be eligible for the study

1. has an active malignancy or history of solid or hematological malignancies within 5 years prior to enrollment in the study. patients who had basal or squamous cell carcinoma-in-situ of the skin that was diagnosed > 2 years prior to the study enrollment and not currently being treated are eligible for study enrollment. 2. patient is pregnant or breast-feeding. 3. patient, in the opinion of the investigator, is unlikely to survive for ≥48 hours from the time of screening. 4. patient has any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study. 5. patient with alanine aminotransferase (alt) or aspartate transaminase (ast) > 3x upper limit of normal (uln) and/or total bilirubin > 2xuln at baseline 6. patient requires treatment with the cytochrome p450 1a2 (cyp1a2) inhibitors, ciprofloxacin (cipro®) and/or fluvoxamine (luvox®) 7. patients participating in any other clinical trial with an investigational drug product or procedure 8. recipients of solid organ and/or hematopoietic cell transplantation 9. patient is known to have end stage renal disease (esrd) and was being treated with maintenance hemodialysis or peritoneal dialysis prior to the current hospitalization. note: patients who initiated rrt due to acute kidney injury during their current hospitalization will be eligible for the study

1. has an active malignancy or history of solid or hematological malignancies within 5 years prior to enrollment in the study. patients who had basal or squamous cell carcinoma-in-situ of the skin that was diagnosed > 2 years prior to the study enrollment and not currently being treated are eligible for study enrollment. 2. patient is pregnant or breast-feeding. 3. patient, in the opinion of the investigator, is unlikely to survive for ≥48 hours from the time of screening. 4. patient has any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the patient by their participation in the study. 5. patient with alanine aminotransferase (alt) or aspartate transaminase (ast) > 3x upper limit of normal (uln) and/or total bilirubin > 2xuln at baseline 6. patient requires treatment with the cytochrome p450 1a2 (cyp1a2) inhibitors, ciprofloxacin (cipro®) and/or fluvoxamine (luvox®) 7. patients participating in any other clinical trial with an investigational drug product or procedure 8. recipients of solid organ and/or hematopoietic cell transplantation 9. patient is known to have end stage renal disease (esrd) and was being treated with maintenance hemodialysis or peritoneal dialysis prior to the current hospitalization. note: patients who initiated rrt due to acute kidney injury during their current hospitalization will be eligible for the study